Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
20.00
+0.56 (2.88%)
Jul 28, 2026, 4:00 PM EDT - Market closed
Vor Biopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 169.87 | 396.49 | 81.95 | 31.36 | 57.71 | 119.8 |
Short-Term Investments | 321.65 | 58.72 | 9.98 | 105.82 | 172.54 | 87.67 |
Cash & Short-Term Investments | 491.53 | 455.21 | 91.93 | 137.18 | 230.25 | 207.47 |
Cash Growth | 718.73% | 395.19% | -32.99% | -40.42% | 10.98% | 323.35% |
Other Current Assets | 9.42 | 3.07 | 6.99 | 3.63 | 6.71 | 6.93 |
Total Current Assets | 500.78 | 458.11 | 96.51 | 140.8 | 236.95 | 214.4 |
Net Property, Plant & Equipment | 3.39 | 3.47 | 41.59 | 50.1 | 57.08 | 22.52 |
Other Long-Term Assets | 2.58 | 2.55 | 4.8 | 7.23 | 5.34 | 5.67 |
Total Assets | 506.75 | 464.13 | 142.89 | 198.13 | 299.37 | 242.59 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.04 | 5.13 | 1.51 | 0.82 | 1.77 | 1.55 |
Accrued Expenses | 14.73 | 19.76 | 12.89 | 10.88 | 7.89 | 6.34 |
Current Portion of Leases | 0.31 | 0.28 | 4.22 | 3.83 | 3.27 | 1.84 |
Other Current Liabilities | - | - | - | 0.05 | 0.19 | 0.43 |
Total Current Liabilities | 16.08 | 25.17 | 18.61 | 15.57 | 13.12 | 10.15 |
Long-Term Leases | 2.63 | 2.72 | 27.62 | 31.83 | 35.64 | 16.17 |
Other Long-Term Liabilities | 638.46 | 600.55 | - | - | - | - |
Total Long-Term Liabilities | 641.09 | 603.27 | 27.62 | 31.83 | 35.64 | 16.17 |
Total Liabilities | 657.17 | 628.44 | 46.23 | 47.4 | 48.76 | 26.33 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0 |
Additional Paid-in Capital | 1,223 | 988.6 | 553.62 | 490.87 | 473.59 | 346.38 |
Accumulated Other Comprehensive Income | -0.71 | 0.04 | 0.02 | -0.08 | -0.77 | - |
Retained Earnings | -1,373 | -1,153 | -456.99 | -340.08 | -222.22 | -130.12 |
Total Common Shareholders' Equity | -150.42 | -164.31 | 96.66 | 150.72 | 250.61 | 216.26 |
Shareholders' Equity | -150.42 | -164.31 | 96.66 | 150.72 | 250.61 | 216.26 |
Total Liabilities & Equity | 506.75 | 464.13 | 142.89 | 198.13 | 299.37 | 242.59 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 2.94 | 3 | 31.83 | 35.66 | 38.91 | 18.01 |
Net Cash (Debt) | 488.59 | 452.21 | 60.1 | 101.52 | 191.33 | 189.46 |
Net Cash Growth | 1570.21% | 652.48% | -40.80% | -46.94% | 0.99% | 516.86% |
Net Cash Per Share | 25.63 | 45.81 | 17.49 | 30.22 | 96.75 | 113.33 |
Book Value | -150.42 | -164.31 | 96.66 | 150.72 | 250.61 | 216.26 |
Book Value Per Share | -7.89 | -16.64 | 28.14 | 44.86 | 126.72 | 129.37 |
Tangible Book Value | -150.42 | -164.31 | 96.66 | 150.72 | 250.61 | 216.26 |
Tangible Book Value Per Share | -7.89 | -16.64 | 28.14 | 44.86 | 126.72 | 129.37 |